Welcome to Nimenrix

Nimenrix is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal disease caused by Neiserria meningitidis serogroups A, C, W135 and Y1


1. Nimenrix. Summary of Product Characteristics, United Kingdom, Pfizer Ltd. Available here.

Prescribing Information
Nimenrix™ prescribing information.


< Back to Vaccines Hub


PP-NIM-GBR-0218.  June 2020